Orchestra BioMed (NASDAQ:OBIO) Stock Moved Up to Hold by Wall Street Zen

Wall Street Zen upgraded shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Several other analysts also recently weighed in on OBIO. BTIG Research lifted their price objective on shares of Orchestra BioMed from $10.00 to $12.00 and gave the company a “buy” rating in a research report on Friday. Piper Sandler restated an “overweight” rating on shares of Orchestra BioMed in a research report on Thursday, October 15th. Chardan Capital restated a “buy” rating and issued a $20.00 price target on shares of Orchestra BioMed in a research note on Friday, October 23rd. B. Riley Financial lifted their price target on Orchestra BioMed from $10.00 to $11.00 and gave the company a “buy” rating in a report on Tuesday, September 15th. Finally, Weiss Ratings raised Orchestra BioMed from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 10th. Seven equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $13.29.

Get Our Latest Stock Report on Orchestra BioMed

Orchestra BioMed Stock Performance

Shares of OBIO traded up $1.10 during midday trading on Friday, hitting $7.25. 1,565,234 shares of the stock traded hands, compared to its average volume of 483,382. Orchestra BioMed has a 1-year low of $3.46 and a 1-year high of $7.37. The firm has a market capitalization of $445.51 million, a PE ratio of -9.67 and a beta of 0.56. The company has a debt-to-equity ratio of 4.58, a quick ratio of 8.24 and a current ratio of 7.25. The business’s 50 day moving average price is $5.86 and its two-hundred day moving average price is $4.63.

Orchestra BioMed (NASDAQ:OBIO – Get Free Report) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.10. Orchestra BioMed had a negative net margin of 182.50% and a negative return on equity of 186.93%. The business had revenue of $0.09 million during the quarter, compared to analyst estimates of $0.13 million. Equities research analysts predict that Orchestra BioMed will post -1.53 EPS for the current fiscal year.

Insiders Place Their Bets

In other Orchestra BioMed news, Director Eric Fain purchased 20,000 shares of the firm’s stock in a transaction dated Monday, November 9th. The stock was bought at an average price of $5.00 per share, with a total value of $100,000.00. Following the completion of the purchase, the director owned 119,630 shares in the company, valued at $598,150. This trade represents a 20.07% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director David Pacitti purchased 20,000 shares of the stock in a transaction dated Monday, November 9th. The shares were acquired at an average cost of $5.00 per share, for a total transaction of $100,000.00. Following the completion of the acquisition, the director directly owned 74,750 shares of the company’s stock, valued at approximately $373,750. This trade represents a 36.53% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last quarter, insiders have purchased 58,000 shares of company stock worth $288,560 and have sold 45,000 shares worth $255,600. 7.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Orchestra BioMed

Institutional investors and hedge funds have recently bought and sold shares of the stock. Flat Footed LLC acquired a new position in Orchestra BioMed during the 2nd quarter valued at about $1,084,670. Rice Hall James & Associates LLC acquired a new stake in shares of Orchestra BioMed in the 2nd quarter worth approximately $1,830,000. BlackRock Inc. acquired a new stake in shares of Orchestra BioMed in the 2nd quarter worth approximately $10,832,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of Orchestra BioMed in the 2nd quarter worth approximately $2,771,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Orchestra BioMed in the 2nd quarter worth approximately $372,000. Institutional investors own 53.20% of the company’s stock.

Orchestra BioMed Company Profile

(Get Free Report)

Orchestra BioMed is a medical technology company that develops therapies for cardiovascular and other diseases, often in collaboration with established medical-device companies. Its work focuses on technologies intended to integrate with existing treatment approaches and devices. The company’s lead program, AVIM therapy, is designed to lower blood pressure in people with pacemakers by adjusting the timing of cardiac pacing. Orchestra BioMed is also developing Virtue SAB, a drug-delivery balloon intended to treat coronary artery disease by delivering sirolimus to blood vessels.

Further Reading

Analyst Recommendations for Orchestra BioMed (NASDAQ:OBIO)

Receive News & Ratings for Orchestra BioMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orchestra BioMed and related companies with MarketBeat.com's FREE daily email newsletter.